Updated: 3/20/2025
A recent court ruling and changes in FDA guidance may impact the availability of compounded GLP-1 medications, including tirzepatide and semaglutide.
However, our 503A pharmacy partner has confirmed that they will continue filling prescriptions for compounded GLP-1s, as long as there is a clinically significant difference from the commercially available versions.
Yes! There are no changes to availability at this time. Our 503A pharmacy partner will continue to compound GLP-1 medications under the following conditions:
Reset Solutions continues to work closely with our pharmacy partner to ensure ongoing access.
Yes. While there are no immediate changes, we recommend refilling your prescription as soon as possible to secure your current pricing and avoid potential future disruptions.
If future regulatory changes restrict compounding further, Reset Solutions has a plan in place to ensure you still have access to GLP-1 medications:
These regulations apply to all providers and compounding pharmacies nationwide. If restrictions are enforced, they will affect every clinic offering compounded GLP-1s—not just Reset Solutions.
We are committed to keeping you informed and ensuring continued access to GLP-1 medications at the best available price. Reset Solutions will continue working with our pharmacy partners and evaluating all options to minimize any potential disruptions.